Please note, as a result of COVID-19 this meeting will be available via teleconference only.

Please register for the meeting by using the link below:

https://magellanhealth.zoom.us/webinar/register/WN_L5E-Lg44SOqQzNOfz9tI1g

If you are calling in only through the webinar:

*6 to Toggle mute/unmute and *9 to Raise Hand

After registering, you will receive a confirmation email containing information about joining the webinar.

Agenda

Public Call in toll free: 1-877-853-5247

1. Call to Order – Chair

2. Roll Call

3. Public Comment

The Department's methods for class review are to better utilize the time of the P&T Committee. Classes shown in **Red** are *new classes/new drugs* and **Blue** are classes where **new information exists and industry testimony will be taken. Classes shown in **Green** are classes with no significant changes have been noted and no industry testimony will be taken.

8:00 am

8:05 am

**New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.

AK Treatment Class	Drug Class	Status
Cystic Fibrosis	CFTR Potentiator Agents	BLUE**
	Antibiotics, Inhaled	GREEN
	Pancreatic Enzymes	BLUE**
Central Nervous System	Multiple Sclerosis Agents	BLUE**
	Stimulants & Related Agents	BLUE**
	Sedative Hypnotics	RED**
	Anticonvulsants	RED**
	Antipsychotics – Atypical	BLUE**
	Antidepressants	RED**
	Alzheimer's Agents	RED**
Analgesics	NSAIDS	GREEN
	Analgesics, Opioid – Short Acting	BLUE**
	Analgesics, Opioid – Long-Acting	GREEN
	Neuropathic Pain	GREEN
	Antimigraine Agents	RED**
	Skeletal Muscle Relaxants	BLUE**

4. Class Review, Discussion & Vote

	Restless Leg Syndrome (RLS)	GREEN
Substance Dependence	Smoking Cessation Products	GREEN
	Opioid Dependence	GREEN
	Opioid Reversal Agents	BLUE**
Antiviral Monoclonal Antibodies	Respiratory Syncytial Virus	GREEN

- 5. Break as needed 15 minutes
- 6. Review minutes from September 2022 meeting
- 7. Comments from Committee Members or Chair
- 8. Adjourn

Next Meeting Date: January 20, 2023